Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 240-247, 2006. First published December 29, 2005; 10.1373/clinchem.2005.059501
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplements
Right arrow All Versions of this Article:
clinchem.2005.059501v1
52/2/240    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shipkova, M.
Right arrow Articles by von Ahsen, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shipkova, M.
Right arrow Articles by von Ahsen, N.
Related Collections
Right arrow Drug Monitoring and Toxicology
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2006;52:240-247.)
© 2006 American Association for Clinical Chemistry, Inc.

Drug Monitoring and Toxicology

Measurement of Erythrocyte Inosine Triphosphate Pyrophosphohydrolase (ITPA) Activity by HPLC and Correlation of ITPA Genotype-Phenotype in a Caucasian Population

Maria Shipkova1,a, Kristin Lorenz1, Michael Oellerich2, Eberhard Wieland1 and Nicolas von Ahsen2

1 Central Institute of Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Stuttgart, Germany.
2 Department of Clinical Chemistry, Georg-August-University, Göttingen, Germany.

aAddress correspondence to this author at: Central Institute of Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Kriegsbergstrasse 60, D-70174 Stuttgart, Germany. Fax 49-278-4809; e-mail m.shipkova{at}klinikum-stuttgart.de.

Background: Inosine triphosphate (ITP) pyrophosphohydrolase (ITPA) catalyzes the pyrophosphohydrolysis of ITP/dITP and xanthosine triphosphate to prevent incorporation of unusual nucleotides into RNA and DNA. Important mutations leading to enzyme deficiency are 94C>A and IVS2 + 21A>C. An association between ITPA 94C>A and adverse reactions during azathioprine treatment has been shown. To investigate the ITPA phenotype, an HPLC procedure was developed and phenotype-genotype correlations were assessed.

Methods: The enzymatic conversion of ITP to inosine monophosphate (IMP) was terminated by perchloric acid and saturated dipotassium hydrogen phosphate. We quantified the IMP at 262 nm after separation on an Aqua perfect C18 column using 20 mmol/L phosphate buffer, pH 2.5. We also genotyped samples for ITPA 94C>A and IVS2 + 21A>C by real-time fluorescence PCR.

Results: The assay was linear to 3 mmol/L IMP [~500 µmol/(g Hb · h)] with a lower limit of quantification of 4 µmol/L [~0.5 µmol/(g Hb · h)]. With IMP-enriched samples, within- and between-day imprecision was ≤3.6% and ≤4.9%, respectively, and the inaccuracy was ≤5.2%. With pooled erythrocytes, within- and between-day imprecision was 3.8% and 7.5%, respectively. ITPA activity in 130 healthy controls was between <0.5 and 408 µmol IMP/(g Hb · h). Mutant allele frequencies were 0.062 (94C>A) and 0.131 (IVS2 + 21A>C). When we used a cutoff of 125 µmol IMP/(g Hb · h), phenotyping detected all 94C>A mutant cases, all 94C>A and IVS2 + 21A>C compound heterozygotes, all IVS2 + 21A>C homozygotes, and 6 of 24 IVS2 + 21A>C heterozygote-only cases. A novel IVS2 + 68T>C mutation was also found.

Conclusions: The HPLC procedure provides an excellent ITPA phenotype-genotype correlation and led to the discovery of a novel IVS2 + 68T>C mutation. The method could facilitate investigation of the role of ITPA activity for drug toxicity during thiopurine therapy.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
D. Friedecky, J. Tomkova, and T. Adam
Determination of ITPase Activity by Capillary Electrophoresis
Clin. Chem., June 1, 2007; 53(6): 1164 - 1165.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Stenmark, P. Kursula, S. Flodin, S. Graslund, R. Landry, P. Nordlund, and H. Schuler
Crystal Structure of Human Inosine Triphosphatase: SUBSTRATE BINDING AND IMPLICATION OF THE INOSINE TRIPHOSPHATASE DEFICIENCY MUTATION P32T
J. Biol. Chem., February 2, 2007; 282(5): 3182 - 3187.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.